Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease

Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdelmoniem Moustafa, Mohammad Ruzieh, Ehab Eltahawy, Saima Karim
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019
Materias:	atrial fibrillation cad dual antiplatelet therapy triple antithrombotic therapy Medicine R
Acceso en línea:	https://doaj.org/article/744980a3a9724d1cb85acc9fb9d3f2b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:744980a3a9724d1cb85acc9fb9d3f2b4
record_format	dspace
spelling	oai:doaj.org-article:744980a3a9724d1cb85acc9fb9d3f2b42021-12-02T17:58:13ZAntithrombotic therapy in patients with atrial fibrillation and coronary artery disease2231-07702249-446410.4103/ajm.AJM_73_19https://doaj.org/article/744980a3a9724d1cb85acc9fb9d3f2b42019-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/ajm.AJM_73_19https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but comes at the expense of an increased risk of bleeding. There is a growing body of evidence that the omission of aspirin from TT has the same preventive efficacy in terms of major adverse cardiacvascular and cerebrovascular events (MACCE) with significantly lower bleeding events. The combination of antiplatelet agents and direct oral anticoagulants (DOAC) is a matter of ongoing research. However, initial studies showed favorable safety profile of DOAC over vitamin K antagonist in combination with antiplatelet agents.Abdelmoniem MoustafaMohammad RuziehEhab EltahawySaima KarimThieme Medical and Scientific Publishers Pvt. Ltd.articleatrial fibrillationcaddual antiplatelet therapytriple antithrombotic therapyMedicineRENAvicenna Journal of Medicine, Vol 09, Iss 04, Pp 123-128 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	atrial fibrillation cad dual antiplatelet therapy triple antithrombotic therapy Medicine R
spellingShingle	atrial fibrillation cad dual antiplatelet therapy triple antithrombotic therapy Medicine R Abdelmoniem Moustafa Mohammad Ruzieh Ehab Eltahawy Saima Karim Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
description	Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but comes at the expense of an increased risk of bleeding. There is a growing body of evidence that the omission of aspirin from TT has the same preventive efficacy in terms of major adverse cardiacvascular and cerebrovascular events (MACCE) with significantly lower bleeding events. The combination of antiplatelet agents and direct oral anticoagulants (DOAC) is a matter of ongoing research. However, initial studies showed favorable safety profile of DOAC over vitamin K antagonist in combination with antiplatelet agents.
format	article
author	Abdelmoniem Moustafa Mohammad Ruzieh Ehab Eltahawy Saima Karim
author_facet	Abdelmoniem Moustafa Mohammad Ruzieh Ehab Eltahawy Saima Karim
author_sort	Abdelmoniem Moustafa
title	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
title_short	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
title_full	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
title_fullStr	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
title_full_unstemmed	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
title_sort	antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2019
url	https://doaj.org/article/744980a3a9724d1cb85acc9fb9d3f2b4
work_keys_str_mv	AT abdelmoniemmoustafa antithrombotictherapyinpatientswithatrialfibrillationandcoronaryarterydisease AT mohammadruzieh antithrombotictherapyinpatientswithatrialfibrillationandcoronaryarterydisease AT ehabeltahawy antithrombotictherapyinpatientswithatrialfibrillationandcoronaryarterydisease AT saimakarim antithrombotictherapyinpatientswithatrialfibrillationandcoronaryarterydisease
_version_	1718379053464944640

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease

Ejemplares similares